A Comparison of Adding Exenatide with Switching to Exenatide in Patients with Type 2 Diabetes Experiencing Inadequate Glycemic Control with Sitagliptin plus Metformin

Exclusion Criteria

• -Are currently enrolled in, or discontinued within the last 30 days (or
• longer, if local guidelines require) from, a clinical trial involving an
• off-label use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically
• compatible with this study.
• -Have previously completed or withdrawn from this study or any other
• study investigating exenatide.
• -Have a known allergy or hypersensitivity to exenatide, sitagliptin or
• excipients contained in exenatide or sitagliptin.
• -Used drugs for weight loss (for example, orlistat, sibutramine,
• phenylpropanolamine, or similar over-the-counter medications) within 1 month of screening.
• -Are currently treated with any of the following excluded medications:
• o Thiazolidinediones (TZD) within 3 months of screening.
• o Sulfonylurea (SU) within 3 months of screening.
• o Dipeptidyl peptidase-4 [DPP-4] inhibitors, with the exception of
• sitagliptin, within 3 months of screening.
• o Meglitinide derivatives (for example, repaglinide or
• nateglinide) within 3 months of screening.
• o Alpha-glucosidase inhibitors (for example, miglitol or
• acarbose) within 3 months of screening.
• o Exogenous insulin within the 3 months prior to screening.
• o Drugs that directly affect gastrointestinal motility, including,
• but not limited to: metoclopramide, cisapride, and chronic
• macrolide antibiotics.
• o Systemic corticosteroids (excluding topical and inhaled
• preparations) by oral, intravenous (IV), or intramuscular
• (IM) route used regularly (for longer than 1 month) or used
• within 1 month immediately prior to screening.
• o Any other oral antidiabetic (OAD) agent, other than sitagliptin or
• metformin, within 3 months prior to screening.